...
首页> 外文期刊>Journal of thermal analysis and calorimetry >Evaluation of carvedilol compatibility with lipid excipients for the development of lipid-based drug delivery systems
【24h】

Evaluation of carvedilol compatibility with lipid excipients for the development of lipid-based drug delivery systems

机译:评价卡维地洛与脂质赋形剂的相容性,以开发基于脂质的药物递送系统

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Carvedilol (CARV) is a widely used non-selective beta-blocker, which has shown low bioavailability after oral administration (20 %) due to its low water solubility and intense first-pass metabolism. Lipid-based drug delivery systems have been proposed to improve CARV oral bioavailability. An evaluation of drug-excipient compatibility is needed to clarify potential physical and chemical interactions between them and therefore guarantee a correct selection of excipients. However, to date there are no reports on the systematic evaluation of CARV-lipid excipient compatibility. Thus, the aim of this study was to evaluate the compatibility of CARV with the lipid excipients commonly used for the development of lipid-based formulations. Thermal analysis techniques (DTA and TG/DTG), Fourier transform infrared spectroscopy and isothermal stress testing (IST) were used for this purpose. The results of this study showed that 4 of the 10 lipid excipients studied were incompatible with CARV. The strongest thermal and spectroscopic modifications were observed in CARV mixtures with oleic acid, lauric acid, lauroyl polyoxylglycerides (Gelucire(A (R)) 44/14) and glyceryl caprylate/caprate (Capmul(A (R)) MCM). In addition, these mixtures resulted in significant decreases in drug content after aging. On the other hand, palmitic acid, stearic acid, glyceryl behenate (Compritol ATO(A (R)) 188), tribeheninPEG (Emulium(A (R)) 22), polyglyceryl-6-isostearate (Plurol Isostearique(A (R))) and diethylene glycol monoethyl ether (Transcutol HPA (R)) were considered good candidates for developing self-emulsifying drug delivery systems and for preparing lipid microparticle or nanoparticle containing CARV. These findings denote the relevance of combining thermal and spectroscopic techniques with thermal stress testing for the accurate determination of drug-lipid excipient compatibility.
机译:卡维地洛(CARV)是一种广泛使用的非选择性β受体阻滞剂,由于其低水溶性和强烈的首过代谢,口服后生物利用度低(20%)。已经提出基于脂质的药物递送系统以改善CARV口服生物利用度。需要评估药物与赋形剂的相容性,以阐明它们之间潜在的物理和化学相互作用,从而保证正确选择赋形剂。然而,迄今为止,尚无关于CARV-脂质赋形剂相容性系统评价的报道。因此,本研究的目的是评估CARV与通常用于开发基于脂质的制剂的脂质赋形剂的相容性。为此使用了热分析技术(DTA和TG / DTG),傅立叶变换红外光谱和等温应力测试(IST)。这项研究的结果表明,所研究的10种脂质赋形剂中有4种与CARV不相容。在CARV与油酸,月桂酸,月桂酰聚氧化甘油酯(Gelucire(A)44/14)和辛酸甘油酯/癸酸甘油酯(Capmul(A)MCM)的混合物中观察到最强的热和光谱修饰。另外,这些混合物导致衰老后药物含量显着降低。另一方面,棕榈酸,硬脂酸,山hen酸甘油酯(Compritol ATO(A(R))188),tribeheninPEG(Emulium(A(R))22),聚-6-异硬脂酸甘油酯(Plurol Isostearique(A(R)) ))和二甘醇单乙醚(Transcutol HPA(R))被认为是开发自乳化药物递送系统和制备含CARV的脂质微粒或纳米微粒的良好选择。这些发现表明将热和光谱技术与热应力测试相结合对于准确确定药物-脂质赋形剂相容性的相关性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号